Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC31526 Insulin levels modulator Insulin levels modulator could be used to treat diabetes. Insulin levels modulator  Chemical Structure
  3. GC31303 Insulin(cattle) (Insulin from bovine pancreas) Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin(cattle) (Insulin from bovine pancreas)  Chemical Structure
  4. GC17158 IRAK inhibitor 1

    IRAK4-IN-1

    An IRAK4 inhibitor IRAK inhibitor 1  Chemical Structure
  5. GC12651 IRAK inhibitor 2 IRAK inhibitor 2  Chemical Structure
  6. GC11103 IRAK inhibitor 3 IRAK inhibitor 3  Chemical Structure
  7. GC16264 IRAK inhibitor 4 IRAK inhibitor 4  Chemical Structure
  8. GC36328 IRAK inhibitor 4 trans IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 trans  Chemical Structure
  9. GC17371 IRAK inhibitor 6 An IRAK4 inhibitor IRAK inhibitor 6  Chemical Structure
  10. GC15999 IRAK-1-4 Inhibitor I A benzimidazole IRAK-1-4 Inhibitor I  Chemical Structure
  11. GC62583 IRAK-4 protein kinase inhibitor 2 IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. IRAK-4 protein kinase inhibitor 2  Chemical Structure
  12. GC31688 IRAK4-IN-1 IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM. IRAK4-IN-1  Chemical Structure
  13. GC71135 IRAK4-IN-20 IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20  Chemical Structure
  14. GC69288 IRAK4-IN-21

    IRAK4-IN-21 (Compound 17) is an orally effective and selective potent IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. It can effectively inhibit the production of IL-23 (IC50=0.17 μM) and may be used in research on autoimmune diseases such as psoriasis vulgaris and psoriatic arthritis.

    IRAK4-IN-21  Chemical Structure
  15. GC69289 IRAK4-IN-22

    IRAK4-IN-22 (compound 18) is an orally effective and selective potent IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 can effectively inhibit the production of IL-23 (IC50=0.10 μM), which can be used in research on autoimmune diseases such as psoriasis vulgaris and psoriatic arthritis.

    IRAK4-IN-22  Chemical Structure
  16. GC38799 IRAK4-IN-4 IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. IRAK4-IN-4  Chemical Structure
  17. GC61944 IRAK4-IN-6 IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma. IRAK4-IN-6  Chemical Structure
  18. GC13961 ISCK03

    c-Kit Inhibitor II,Stem-Cell Factor/c-Kit Inhibitor

    inhibitor of SCF-mediated c-kit activation ISCK03  Chemical Structure
  19. GC12167 ITK inhibitor

    Potent ITK inhibitor

    ITK inhibitor  Chemical Structure
  20. GC36354 ITK inhibitor 2 ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC50 of 2 nM. ITK inhibitor 2  Chemical Structure
  21. GC16869 Ixabepilone

    Azaepothilone B, BMS-247550

    A broad-spectrum anticancer agent Ixabepilone  Chemical Structure
  22. GC62500 JAK2-IN-7 JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities. JAK2-IN-7  Chemical Structure
  23. GC62665 JAK2/FLT3-IN-1 TFA JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity. JAK2/FLT3-IN-1 TFA  Chemical Structure
  24. GC50706 JBJ-03-142-02 JBJ-03-142-02  Chemical Structure
  25. GC62632 JBJ-04-125-02

    JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities.

    JBJ-04-125-02  Chemical Structure
  26. GC67690 JBJ-09-063 hydrochloride

    JBJ-09-063 hydrochloride is a mutation selective allosteric EGFR inhibitor

    JBJ-09-063 hydrochloride  Chemical Structure
  27. GC67860 JBJ-09-063 TFA JBJ-09-063 TFA  Chemical Structure
  28. GC19205 JH-II-127 JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor, with IC50 of 6.6 nM, 2.2 nM ,47.7 nM for LRRK2-wild-type, LRRK2-G2019S, LRRK2-A2016T. JH-II-127  Chemical Structure
  29. GC33062 JH-VIII-157-02 JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells. JH-VIII-157-02  Chemical Structure
  30. GC63925 JH-X-119-01 JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01  Chemical Structure
  31. GC18168 JI-101

    CGI1842

    An orally active inhibitor

    JI-101  Chemical Structure
  32. GC65436 JND3229 JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma. JND3229  Chemical Structure
  33. GC18030 JNJ 28871063 hydrochloride ErbB receptor family inhibitor JNJ 28871063 hydrochloride  Chemical Structure
  34. GC38502 JNJ-10198409 A potent PDGF tyrosine kinase inhibitor JNJ-10198409  Chemical Structure
  35. GC14544 JNJ-10198409 inhibitor of platelet-derived growth factor (PDGF-BB) tyrosine kinase JNJ-10198409  Chemical Structure
  36. GC12585 JNJ-38877605 C-Met inhibitor,ATP-competitive JNJ-38877605  Chemical Structure
  37. GC33266 JNJ-38877618 JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively. JNJ-38877618  Chemical Structure
  38. GC32995 JNJ-47117096 hydrochloride (MELK-T1 hydrochloride)

    MELK-T1 hydrochloride

    JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM. JNJ-47117096 hydrochloride (MELK-T1 hydrochloride)  Chemical Structure
  39. GC70499 JNJ-49095397 JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397  Chemical Structure
  40. GC69318 JNJ-61803534

    JNJ-61803534 is an effective and orally active RORγt inverse agonist with an IC50 of 9.6 nM. It has anti-inflammatory activity and inhibits the production of IL-17A in human CD4+ T cells under Th17 differentiation conditions.

    JNJ-61803534  Chemical Structure
  41. GC69321 JTE-952

    JTE-952 is an orally active, type II selective inhibitor of colony-stimulating factor-1 receptor (CSF-1R/cFMS) that effectively inhibits CSF1R and TrkA with IC50 values of 13 nM and 261 nM, respectively. It can be used for research related to arthritis.

    JTE-952  Chemical Structure
  42. GC11362 K 252a

    SF 2370

    A protein kinase inhibitor K 252a  Chemical Structure
  43. GN10497 Kaempferitrin

    BRN 0073958, Grosvenorine II, Kaempferol 3,7-O-α-Dirhamnoside, Lespedin

    Kaempferitrin  Chemical Structure
  44. GC17638 KB SRC 4 KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity. KB SRC 4  Chemical Structure
  45. GC32625 KDR-in-4

    KDR-in-4

    KDR-in-4 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM. KDR-in-4  Chemical Structure
  46. GC63943 KH-CB20 KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and the closely related isoform CLK4, with an IC50 of 16.5 nM for CLK1. KH-CB20  Chemical Structure
  47. GC13264 Ki20227

    Ki 20227;Ki-20227

    A c-Fms kinase inhibitor Ki20227  Chemical Structure
  48. GC11666 Ki8751 VEGFR-2 inhibitor,potent and selective Ki8751  Chemical Structure
  49. GC72285 KLTWQELYQLKYKGI KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF. KLTWQELYQLKYKGI  Chemical Structure
  50. GC13902 KRCA 0008 Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor KRCA 0008  Chemical Structure
  51. GC12590 KRN 633 VEGFR inhibitor,ATP-competitive KRN 633  Chemical Structure
  52. GC10626 KU14R KU14R  Chemical Structure
  53. GC14592 KW 2449 A multi-kinase inhibitor KW 2449  Chemical Structure
  54. GC10523 KX1-004 Pp60c-src inhibitor KX1-004  Chemical Structure
  55. GC14288 KX2-391

    KX 01, Tirbanibulin

    KX2-391 (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. KX2-391  Chemical Structure
  56. GC10222 KX2-391 dihydrochloride A Src kinase inhibitor KX2-391 dihydrochloride  Chemical Structure
  57. GC50137 KYL KYL, an antagonistic peptide, selectively targets EphA4 receptor. KYL  Chemical Structure
  58. GC32044 L 601920-0 (Methyl-3β-hydroxycholenate) L 601920-0 (Methyl-3β-hydroxycholenate) is a ROR gamma modulator extracted from patent US20110263046 A1, in figure 2. L 601920-0 (Methyl-3β-hydroxycholenate)  Chemical Structure
  59. GC44085 L-Sulforaphene

    Raphanin, (S)-Sulforaphene

    L-Sulforaphene, isolated from radish seeds, exhibits an ED50 against velvetleaf seedlings approximately 2 x 10-4 M. L-Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, p-ERK1/2, NF‐κB and other signals. L-Sulforaphene  Chemical Structure
  60. GC36423 Lanraplenib

    GS-9876, GS-SYK

    A Syk inhibitor Lanraplenib  Chemical Structure
  61. GC38630 Lanraplenib succinate

    GS-9876 succinate

    Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate  Chemical Structure
  62. GC13608 Lapatinib

    GW572016; GW2016

    A dual inhibitor of EGFR and ErbB2 Lapatinib  Chemical Structure
  63. GC25559 Lapatinib (GW-572016) Ditosylate

    GW-572016

    Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib (GW-572016) Ditosylate  Chemical Structure
  64. GC16593 Lapatinib Ditosylate

    GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate

    Lapatinib Ditosylate is a selective dual inhibitor of ErbB-2 and EGFR with IC50 value against ErbB-2 and EGFR of 9.2 and 10.8 nM in vitro, respectively. Lapatinib Ditosylate  Chemical Structure
  65. GC67759 Lapatinib-d4

    GW572016-d4; GW2016-d4

    Lapatinib-d4  Chemical Structure
  66. GC69356 Laprituximab

    J2898A

    Laprituximab (J2898A) is a humanized IgG1 antibody against EGFR that can be used to synthesize ADC IMGN289.

    Laprituximab  Chemical Structure
  67. GC69358 Larotinib mesylate hydrate

    Larotinib mesylate hydrate is an effective, broad-spectrum, orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target, with an IC50 of 0.6 nM.

    Larotinib mesylate hydrate  Chemical Structure
  68. GC16021 Lavendustin A

    NSC 678027, RG-14355

    EGFR tyrosine kinase inhibitor Lavendustin A  Chemical Structure
  69. GC19218 Lazertinib

    YH25448

    Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. Lazertinib  Chemical Structure
  70. GC70315 LCB 03-0110 LCB 03-0110, a thienopyridine derivative, is a potent pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor. LCB 03-0110  Chemical Structure
  71. GC13117 Lck Inhibitor

    Lymphocyte-specific Protein Tyrosine Kinase, RK-24466

    A selective inhibitor of lymphocyte-specific protein tyrosine kinase Lck Inhibitor  Chemical Structure
  72. GC36430 Lck inhibitor 2 Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively Lck inhibitor 2  Chemical Structure
  73. GC14241 LDC1267 TAM kinase inhibitor,highly selective LDC1267  Chemical Structure
  74. GC14552 LDK378

    LDK 378;LDK-378;Ceritinib

    LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. LDK378  Chemical Structure
  75. GC17452 LDK378 dihydrochloride LDK378 dihydrochloride  Chemical Structure
  76. GC50327 LDN 193189 dihydrochloride

    DM-3189

    Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs LDN 193189 dihydrochloride  Chemical Structure
  77. GC33086 LDN-192960 LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively. LDN-192960  Chemical Structure
  78. GC44047 LDN-192960 (hydrochloride) LDN-192960 is an inhibitor of haspin protein kinase and dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) with IC50 values of 10 and 48 nM, respectively. LDN-192960 (hydrochloride)  Chemical Structure
  79. GC38403 LDN-192960 hydrochloride LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively. LDN-192960 hydrochloride  Chemical Structure
  80. GC16580 LDN-193189

    LDN 193189;LDN193189

    ALK inhibitor,potent and selective LDN-193189  Chemical Structure
  81. GC16798 LDN-211904 LDN-211904 (compound 32) is a potent and selective EphB3 inhibitor with an IC50 of 0.079 μM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC. LDN-211904  Chemical Structure
  82. GC17035 LDN-212854 BMP receptor inhibitor,potent and selective LDN-212854  Chemical Structure
  83. GC13225 LDN-214117 potent and selective ALK2 inhibitor LDN-214117  Chemical Structure
  84. GC14931 LDN193189 Hydrochloride

    LDN 193189 hydrochloride; LDN-193189 hydrochloride

    LDN193189 Hydrochloride is a selective inhibitor of the transcriptionally active morphogenetic protein (BMP) type I receptor, a family of BMP receptors that includes activin receptor-like kinases (ALK1, ALK2, ALK3, and ALK6). LDN193189 Hydrochloride inhibits ALK2 and ALK3 with IC50 values of 5nM and 30nM, respectively. LDN193189 Hydrochloride  Chemical Structure
  85. GC15454 Lenvatinib (E7080)

    E-7080, ER-203492-00

    Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. Lenvatinib (E7080)  Chemical Structure
  86. GC36438 Lenvatinib mesylate

    E-7080

    An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate  Chemical Structure
  87. GC17033 Lestaurtinib

    CEP-701; KT-5555

    A potent JAK2 and PRK1 kinase inhibitor Lestaurtinib  Chemical Structure
  88. GC17958 Linifanib (ABT-869)

    Linifanib

    Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. Linifanib (ABT-869)  Chemical Structure
  89. GC15749 Linsitinib

    OSI 906; OSI-906; OSI906

    IGF1R/IR inhibitor,potent and novel Linsitinib  Chemical Structure
  90. GC47570 Lipoxygenin An inhibitor of 5-LO Lipoxygenin  Chemical Structure
  91. GC17835 LM 22A4 tropomyosin-related kinase B (TrkB) agonist LM 22A4  Chemical Structure
  92. GC30770 LM22B-10 An activator of TrkB and TrkC LM22B-10  Chemical Structure
  93. GC36425 LOXO-101 (Larotrectinib)

    ARRY-470, Larotrectinib

    LOXO-101 (Larotrectinib) (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). LOXO-101 (Larotrectinib)  Chemical Structure
  94. GC15282 LOXO-101 (Larotrectinib) sulfate LOXO-101 (Larotrectinib) sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). LOXO-101 (Larotrectinib) sulfate  Chemical Structure
  95. GC19547 LOXO-292

    selpercatinib

    LOXO-292 (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. LOXO-292 has anticancer activity. LOXO-292  Chemical Structure
  96. GC65390 LRRK2 inhibitor 1 LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC50 of 6.8. LRRK2 inhibitor 1  Chemical Structure
  97. GC10809 LRRK2-IN-1

    Leucine-rich repeat kinase 2 IN-1

    A selective LRRK2 inhibitor LRRK2-IN-1  Chemical Structure
  98. GC69402 LRRK2-IN-7

    LRRK2-IN-7 is an effective, selective, CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. The selectivity of LRRK2-IN-7 is over 1000-fold for other kinases, ion channels and CYP enzymes.

    LRRK2-IN-7  Chemical Structure
  99. GC69410 Lumretuzumab

    Anti-Human ERBB3 Recombinant Antibody

    Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized monoclonal antibody that targets HER3 (ERBB3) and can be used for cancer research.

    Lumretuzumab  Chemical Structure
  100. GC13848 LY2784544

    Gandotinib

    Potent inhibitor of JAK2 LY2784544  Chemical Structure
  101. GC11057 LY2801653

    Merestinib

    A MET kinase inhibitor LY2801653  Chemical Structure

Items 601 to 700 of 1198 total

per page
  1. 5
  2. 6
  3. 7
  4. 8
  5. 9

Set Descending Direction